drugset
drugset / Trial / NCT04260191

Study of AMG 910 in Subjects With CLDN18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma

NCT04260191 ↗

Phase 1 Terminated 15 enrolled Amgen
Non-randomizedSequentialOpen-labelTreatment

Summary

To evaluate the safety and tolerability of AMG 910 in adult subjects, and to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D)

Timeline

Start
2020-06-29
Primary completion
2022-06-02
Completion
2022-06-02

Outcome

Outcome not reported

Stopped (Business): “Business Decision”

Drugs

EvaluationDrugModalityDoseRoute
Subject AMG 910 Other / unclassified 6.5 ug Intravenous
Subject AMG 910 Other / unclassified 15 ug Intravenous

Indications

gastroesophageal adenocarcinoma